SCHEMBL2085259

SCHEMBL2085259

Pc1ccc(-c2ccccc2)c(C2CCCCC2)c1C1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.38
ADORA2B P29275 2/20 0.38
ADORA1 P30542 2/20 0.38
ADORA2A P29274 1/20 0.38
POLB P06746 1/20 0.37
CASP3 P42574 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAT2A P31153 3/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PTGS2 P35354 1/20 0.35
PSMB8 P28062 1/20 0.34
PSMB5 P28074 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68108 0.77 PTGS2 (0.39) ADORA3ADORA2BADORA1ADORA2APOLB
SCHEMBL28214434 0.76 TDP1 (0.37) ADORA3ADORA2BADORA1ADORA2APOLB
SCHEMBL19884554 0.75 PDK2 (0.43) ADORA3ADORA2BADORA1ADORA2APOLB
SCHEMBL5663657 0.75 POLB (0.40) POLBCASP3SENP7SENP6TDP1
SCHEMBL14874646 0.75 ALDH1A1 (0.38) ADORA3ADORA2BADORA1ADORA2APOLB
SCHEMBL8151002 0.74 ALDH1A1 (0.50) ADORA3ADORA2BADORA1ADORA2APOLB
SCHEMBL28816105 0.74 CHRNB2 (0.57) ADORA3ADORA2BADORA1ADORA2APOLB
SCHEMBL4476579 0.74 CHRNB2 (0.57) ADORA3ADORA2BADORA1ADORA2APOLB
Phosphine SCHEMBL2085260 0.72 CHRNB2 (0.59) ADORA3ADORA2BADORA1ADORA2APOLB
SCHEMBL28152698 0.72 PTGS2 (0.39) ADORA3ADORA2BADORA1ADORA2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927721-B2 Naphthyridine derivative SHIONOGI & CO., LTD. (JP) 2015-01-06 US disclosed
US-8895548-B2 Pharmaceutical composition for treating alzheimer's disease SHIONOGI & CO., LTD. (JP) 2014-11-25 US disclosed
US-20140058097-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE SHIONOGI & CO., LTD. (JP) 2014-02-27 US disclosed
US-8653067-B2 Pharmaceutical composition for treating Alzheimer's disease SHIONOGI & CO., LTD. (JP) 2014-02-18 US disclosed
EP-2634186-A1 NAPHTHYRIDINE DERIVATIVE Shionogi&Co., Ltd. (JP) 2013-09-04 EP disclosed
US-20130217705-A1 NAPHTHYRIDINE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2013-08-22 US disclosed
US-7863332-B2 Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-01-04 US disclosed
US-20100160290-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE SHIONOGI & CO., LTD. (JP) 2010-06-24 US disclosed
EP-2151435-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALZHEIMER'S DISEASE Shionogi&Co., Ltd. (JP) 2010-02-10 EP disclosed
EP-1781297-B1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-10-15 EP disclosed
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-13 US disclosed
EP-1781297-A1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2007-05-09 EP disclosed
WO-2006018326-A1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD ADORA3 466/4885ADORA2B 683/4885ADORA1 361/4885
US-20100160290-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE NR1H2, NR1H3, NR0B1 ADORA3 163/4885ADORA2B 85/4885ADORA1 81/4885
US-20140058097-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE NR1H2, NR1H3, NR0B1 ADORA3 181/4885ADORA2B 88/4885ADORA1 91/4885
US-20130217705-A1 NAPHTHYRIDINE DERIVATIVE BACE1, BACE2, APP ADORA3 1889/4885ADORA2B 742/4885ADORA1 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.